Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1600 participants.

Also called NCT03080935

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,600 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03080935
  • EudraCT 2016-004066-26
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Belgium, Denmark, France, Germany, Italy, Portugal, Sweden (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03080935. Allocation not applicable; no masking; primary purpose treatment. Start 2017-03-13 (actual); primary completion 2022-03-04 (actual). Results posted on 2023-01-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
Condition
Dyslipidemia
Intervention (Drug)
Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct03080935
Content hash
532791421e4531fa0d8e999c1a285677ba9aaa12f88ba66491fb5d7627fdc6c3